Table 47.4—Potential Short-Term Benefits and Risks of Testosterone Supplementation in Older Men With Low-Normal or Mildly Decreased Testosterone Levels
|
Study End Point |
Effect of Testosterone |
|
Lean body mass |
Increased |
|
Fat mass |
Decreased |
|
Bone mineral density |
Variable |
|
Strength |
Variable Improved strength and performance of some functional tasks in some studies |
|
Sexual function |
Variable Activation in sexual behavior and increased libido (most consistent findings) |
|
Mood |
Variable Mood, subjective well-being improved (in some studies) |
|
Cognitive |
Some cognitive domains improved Worsened effect of practice on verbal fluency |
|
Lipid profile |
Decreased total, LDL cholesterol HDL cholesterol unchanged |
|
Coronary heart disease |
In men with established disease, improved ECG evidence of exercise-induced coronary ischemia (in most studies) Variable effect on angina pectoris |
|
Prostate |
PSA increased slightly in many patients No effect on voiding symptoms, prostate examination |
|
Hematocrit |
Increased 2.5% to 5% versus baseline Erythrocytosis developed in 6% to 25% of subjects |
|
Long-term clinical outcomes |
Unknown |
NOTE: This table summarizes results of placebo-controlled studies. LDL = low-density lipoprotein; HDL = high-density lipoprotein; ECG = electrocardiographic; PSA = prostate-specific antigen.